Skip to content
AT-NCIGT - The National Center for Advanced Technologies for Image Guided Therapy

Ferenc Jolesz First Monday Research Seminar Series

The Department of Radiology holds a monthly Ferenc Jolesz Seminar Series presented by Harvard Medical School investigators, as well as speakers from other institutions, on a wide range of topics related to image-guided therapy.
These seminars honor the late FERENC JOLESZ, MD who founded the multidisciplinary image-guided therapy program at Brigham and Women’s Hospital and is widely known as a founding father of the field of image-guided therapy.

UPCOMING SEMINARS

DATE: Monday, June 2nd, 2025 | TIME: 12:15pm-1:15pm | LOCATION: This seminar will be held in the ANESTHESIA LECTURE HALL .

Located at 45 Francis Street entrance on the L1 level. Enter through the sliding doors at the 45 Francis Street entrance, go straight through the lobby. You will be on the 2nd floor. Take a left onto the 2nd floor hallway called “the Pike”. Continue straight until you see the Mary Horrigan Connors elevators on your right. Take these elevators to level L1. When you exit the elevators, look directly to your left. There will be a set of double doors with a sign for the Anesthesia Department. Enter through these double doors and continue straight until you reach a wall. Make a left and the room will be straight ahead.

Olivier Clerc, MD: Unraveling Cardiac Amyloidosis: From Multi-Modality Imaging to Next-Generation Proteomics

Olivier Clerc

Olivier Clerc, MD

Research Scientist
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology
Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine
Brigham and Women’s Hospital

This presentation will first review cardiac amyloidosis and the role of imaging in the diagnosis of the disease. Then, recent research conducted by Olivier Clerc and Prof. Dorbala’s team will be presented. The main focus will be on quantitative PET imaging with novel amyloid-binding radiotracers as well as on advanced MRI metrics. These imaging methods have the potential to improve the detection of early and rare forms cardiac amyloidosis, to specifically measure disease changes over time, and to achieve accurate risk stratification. Recent key findings in SPECT and echocardiography will also be covered. Particular attention will be given to the promising ability of these imaging methods to characterize myocardial contents and properties in amyloidosis, leading to a better understanding of the pathophysiology of the disease. Finally, we will transition to the initial steps of Olivier Clerc’s K99 grant project that joins imaging and proteomics to elucidate the mechanisms of cardiac dysfunction in amyloidosis.

Olivier is a research scientist in the cardiac amyloidosis imaging research team led by Prof. Dorbala. He graduated from medical school at Lausanne University in Switzerland, with a MD thesis on cardiovascular prevention. Then, he completed residencies in internal medicine in Geneva, Neuchatel and Zurich. After that, he became a clinical and research fellow in cardiac imaging at University Hospital Zurich in Prof. Kaufmann’s team, where he was trained in multi-modality imaging and studied essentially SPECT and CT in coronary artery disease. Thereafter, he competed cardiology fellowships at University Hospital Zurich and at University Hospital Basel, with more research on multi-modality cardiac imaging. Driven by his interest for cardiac amyloidosis, Olivier Clerc joined Prof. Dorbala’s team at Brigham and Women’s Hospital in 2021. His research was then mostly dedicated to PET imaging with novel amyloid-binding radiotracers, such as 124I-evuzamitide and 18F-florbetapir, as well as to cardiac MRI, with further contributions in SPECT and echocardiography. His project on 18F-flutemetamol PET, MRI and stress echocardiography to establish novel imaging metrics and to investigate mechanisms of ATTR amyloidosis was awarded both the BWH Radiology Department Research Pilot Grant Award and the Young Investigator in Cardiac Amyloidosis Research Fellowship Award from the American Society of Nuclear Cardiology and Pfizer. Lastly, Olivier Clerc obtained a K99/R00 Pathway to Independence Award from the NIH and the NHLBI to elucidate mechanisms of cardiac dysfunction by joining imaging and proteomics. He is now conducting the K99 phase on cardiac amyloidosis.

Back To Top